In November 2019, the US Food and Drug Administration (FDA) granted psilocybin therapy a breakthrough status for depression. This recognition makes it the second time in a year the FDA would designate such a status to psilocybin. The hallucinogenic compound in psychedelic mushrooms. The FDA’s action is meant to fast-track the typical slow process of […]
